193 related articles for article (PubMed ID: 8875229)
1. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer.
Guo ZS; Wang LH; Eisensmith RC; Woo SL
Gene Ther; 1996 Sep; 3(9):802-10. PubMed ID: 8875229
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
3. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
4. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes.
Kay MA; Graham F; Leland F; Woo SL
Hepatology; 1995 Mar; 21(3):815-9. PubMed ID: 7875680
[TBL] [Abstract][Full Text] [Related]
7. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.
Song S; Embury J; Laipis PJ; Berns KI; Crawford JM; Flotte TR
Gene Ther; 2001 Sep; 8(17):1299-306. PubMed ID: 11571566
[TBL] [Abstract][Full Text] [Related]
8. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
9. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector.
Hersh J; Crystal RG; Bewig B
Gene Ther; 1995 Mar; 2(2):124-31. PubMed ID: 7719929
[TBL] [Abstract][Full Text] [Related]
10. Liver-directed gene therapy: evaluation of liver specific promoter elements.
Hafenrichter DG; Ponder KP; Rettinger SD; Kennedy SC; Wu X; Saylors RS; Flye MW
J Surg Res; 1994 Jun; 56(6):510-7. PubMed ID: 8015304
[TBL] [Abstract][Full Text] [Related]
11. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
12. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo.
Park F; Kay MA
Mol Ther; 2001 Sep; 4(3):164-73. PubMed ID: 11545606
[TBL] [Abstract][Full Text] [Related]
13. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene.
Sandig V; Löser P; Lieber A; Kay MA; Strauss M
Gene Ther; 1996 Nov; 3(11):1002-9. PubMed ID: 9044740
[TBL] [Abstract][Full Text] [Related]
14. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors.
Tang DC; Johnston SA; Carbone DP
Cancer Gene Ther; 1994 Mar; 1(1):15-20. PubMed ID: 7621233
[TBL] [Abstract][Full Text] [Related]
15. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
Shi CX; Long MA; Liu L; Graham FL; Gauldie J; Hitt MM
Mol Ther; 2004 Oct; 10(4):758-67. PubMed ID: 15451460
[TBL] [Abstract][Full Text] [Related]
16. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral-mediated skeletal muscle transcriptional targeting using chimeric tissue-specific promoters.
Frauli M; Ribault S; Neuville P; Augé F; Calenda V
Med Sci Monit; 2003 Feb; 9(2):BR78-84. PubMed ID: 12601283
[TBL] [Abstract][Full Text] [Related]
18. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.
Schiedner G; Morral N; Parks RJ; Wu Y; Koopmans SC; Langston C; Graham FL; Beaudet AL; Kochanek S
Nat Genet; 1998 Feb; 18(2):180-3. PubMed ID: 9462752
[TBL] [Abstract][Full Text] [Related]
19. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.
Barr D; Tubb J; Ferguson D; Scaria A; Lieber A; Wilson C; Perkins J; Kay MA
Gene Ther; 1995 Mar; 2(2):151-5. PubMed ID: 7719932
[TBL] [Abstract][Full Text] [Related]
20. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
